SAN DIEGO, Oct. 31, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the
Company will release its third quarter 2016 financial results and
provide a corporate update on Monday,
November 7, 2016, after the close of the U.S. financial
markets. The Company will host a conference call and live
webcast with the investment community on Monday, November 7, 2016 at 4:30 p.m. ET.
Conference Call & Webcast Information
When:
November 7, 2016, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: Arena Pharmaceuticals Third Quarter 2016 Conference
Call
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website at:
www.arenapharma.com. A replay of the conference call will be
archived under the investor relations section of Arena's website
for 30 days shortly after the call.
About Arena Pharmaceuticals
We are a biopharmaceutical
company focused on developing novel, small molecule drugs across a
range of therapeutic areas. We have three primary proprietary
investigational clinical programs: etrasimod (APD334) in Phase 2
evaluation for ulcerative colitis, APD371 entering Phase 2
evaluation for the treatment of pain associated with Crohn's
disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH). Additionally, we have
collaborations with the following pharmaceutical companies: Eisai
Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd.
(Phase 2 candidate), and Boehringer Ingelheim International GmbH
(preclinical candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements Arena's focus, primary programs and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact:
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-third-quarter-2016-financial-results-and-provide-corporate-update-on-monday-november-7-2016-300353728.html
SOURCE Arena Pharmaceuticals, Inc.